Automate Your Wheel Strategy on BIIB
With Tiblio's Option Bot, you can configure your own wheel strategy including BIIB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BIIB
- Rev/Share 68.6623
- Book/Share 124.1985
- PB 1.4314
- Debt/Equity 0.3619
- CurrentRatio 2.7163
- ROIC 0.0778
- MktCap 26080729916.0
- FreeCF/Share 15.5348
- PFCF 11.452
- PE 16.203
- Debt/Assets 0.2256
- DivYield 0
- ROE 0.0925
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | BIIB | Stifel | Hold | Buy | -- | $202 | Nov. 6, 2025 |
| Initiation | BIIB | Jefferies | -- | Buy | -- | $190 | Sept. 25, 2025 |
| Resumed | BIIB | Truist | -- | Hold | -- | $142 | July 21, 2025 |
| Downgrade | BIIB | HSBC Securities | Buy | Hold | -- | $118 | April 28, 2025 |
| Downgrade | BIIB | Argus | Buy | Hold | -- | -- | April 4, 2025 |
| Initiation | BIIB | Bernstein | -- | Market Perform | -- | $160 | Feb. 11, 2025 |
| Downgrade | BIIB | Piper Sandler | Overweight | Neutral | $315 | $138 | Jan. 2, 2025 |
| Downgrade | BIIB | BMO Capital Markets | Outperform | Market Perform | $230 | $164 | Dec. 20, 2024 |
| Downgrade | BIIB | Stifel | Buy | Hold | -- | $175 | Dec. 16, 2024 |
| Resumed | BIIB | BofA Securities | -- | Neutral | -- | $178 | Dec. 10, 2024 |
News
Biogen Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
BIIB
Published: February 12, 2025 by: Benzinga
Sentiment: Neutral
Published: February 12, 2025 by: Benzinga
Sentiment: Neutral
Biogen Inc. BIIB will release its fourth-quarter financial results, before the opening bell, on Wednesday, Feb. 12, 2025.
Read More
Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?
ALNY,
BIIB,
GILD,
MRNA,
VRTX
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.
Read More
About Biogen Inc. (BIIB)
- IPO Date 1991-09-17
- Website https://www.biogen.com
- Industry Drug Manufacturers - General
- CEO Christopher A. Viehbacher
- Employees 7605
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.